{"id":"W2806421431","doi":"10.1016/s1470-2045(18)30365-6","title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Enzalutamide; PARP inhibitor; Placebo; Clinical endpoint; Docetaxel; Population; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009477966,0.0002744459,0.001284415,0.0001417276,0.0001745739,0.00004397904,0.0001701367,0.00007391293,0.0001931264],"category_scores_gemma":[0.00003678713,0.0001267645,0.00005827348,0.0003685029,0.0005097506,0.0001058433,0.00002481538,0.0003506474,0.0000227546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004132538,"about_ca_system_score_gemma":0.00112257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003716561,"about_ca_topic_score_gemma":0.003256829,"domain_scores_codex":[0.9977214,0.0003794297,0.0004715344,0.0003666703,0.0004233554,0.0006375573],"domain_scores_gemma":[0.9986042,0.0002642942,0.000270338,0.0003938541,0.0003217043,0.0001456153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.990548,0.001978936,0.002998464,0.0000622484,0.0007842664,0.0001291097,0.001175831,0.0000160463,0.0003216652,0.00006827464,0.0005472701,0.001369897],"study_design_scores_gemma":[0.9548543,0.04105736,0.001154525,0.0001045847,0.0005319158,0.000008342437,0.0001534145,0.00009402092,0.0007001543,0.00003906722,0.001146422,0.0001559095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981216,0.0002017394,0.00001220082,0.004527442,0.000183027,0.01222428,0.00005287662,0.00004164697,0.001540841],"genre_scores_gemma":[0.9935496,0.00009567144,0.0002251512,0.0003579934,0.0003955637,0.004039485,0.0001413563,0.00003512228,0.001160016],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03907843,"threshold_uncertainty_score":0.5169308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.063617209979282,"score_gpt":0.3828651709096185,"score_spread":0.3192479609303365,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}